Novolog Shortage Update for 2026

If you depend on Novolog (Insulin Aspart) to manage your diabetes, you've probably heard about — or experienced firsthand — the supply issues that have been affecting this essential medication. In this article, we'll give you the latest update on the Novolog shortage heading into 2026, including what's causing it, how it's affecting patients, and what you can do right now.

Is Novolog Still in Shortage?

The short answer: it depends on where you are. Novolog is not listed as a nationwide shortage by the FDA as of early 2026, but many patients and pharmacies continue to report intermittent availability issues — especially for vial presentations.

Here's the timeline of what happened:

• Early 2024: Novo Nordisk confirmed backorders affecting Novolog vials across the U.S.
• May 2024: Shipping resumed, but supply did not immediately meet demand.
• Late 2024 - 2025: Availability improved, but periodic stock-outs continued at some pharmacies.
• December 31, 2025: Novo Nordisk discontinued its unbranded (generic-like) Insulin Aspart product, pushing more patients back to brand-name Novolog.
• Early 2026: Brand Novolog is generally available, but vials remain harder to find than pens in some regions.

If you're having trouble finding Novolog right now, you're not imagining things. The supply situation has improved significantly from 2024, but it hasn't fully stabilized everywhere.

Why Is Novolog Hard to Find?

Several factors are contributing to ongoing availability challenges:

Discontinuation of Unbranded Insulin Aspart

This is the biggest factor heading into 2026. When Novo Nordisk discontinued its unbranded Insulin Aspart on December 31, 2025, patients and pharmacies that relied on that cheaper option had to shift to brand-name Novolog or find alternatives. This sudden increase in demand for the brand product strained supply.

Growing Diabetes Population

Over 38 million Americans have diabetes, and that number continues to rise. More patients needing rapid-acting insulin means more demand for products like Novolog.

Supply Chain Complexity

Insulin is a biologic product — it's manufactured through complex processes involving living cells. This makes it harder to ramp up production quickly compared to traditional small-molecule drugs. Any disruption in manufacturing, quality control, or distribution can cause ripple effects that last months.

Pharmacy Inventory Management

Large chain pharmacies order based on projected demand. When supply is uncertain, they may reduce inventory levels, leading to more frequent out-of-stock events. This creates a cycle where patients scramble to find stock, increasing demand at other locations.

How Much Does Novolog Cost in 2026?

Cost is a major concern for anyone with diabetes, and Novolog is no exception:

• Without insurance: Expect to pay between $130 and $350 per vial or pen pack, depending on the pharmacy and quantity.
• With the Novo Nordisk savings card: Commercially insured patients can pay as little as $35 per 30-day supply.
• Medicare Part D: Insulin copays are capped at $35 per month per covered product under the Inflation Reduction Act.
• With GoodRx or other coupons: You may find Insulin Aspart for as low as $74 per vial.

For more detailed savings strategies, check out our guide on How to Save Money on Novolog in 2026.

New Options and Developments

The insulin landscape is evolving, and there are some positive developments to be aware of:

Biosimilar and Generic Insulin Options

While Novo Nordisk's unbranded Insulin Aspart was discontinued, other manufacturers continue to offer affordable rapid-acting insulin options. Admelog (Insulin Lispro) by Sanofi and Eli Lilly's authorized generic Insulin Lispro provide lower-cost alternatives. The biosimilar Merilog (Insulin Aspart) may also expand access.

The $35 Insulin Cap

Under the Inflation Reduction Act, Medicare Part D now caps insulin copays at $35 per month. Many state legislatures have also passed insulin copay caps for commercial insurance plans, with caps ranging from $25 to $100 per month depending on the state.

Fiasp as an Alternative

Fiasp, another Insulin Aspart product by Novo Nordisk with ultra-rapid action, may be available when standard Novolog is not. Because it shares the same active ingredient, it's often a seamless switch. Learn about all your options in our post on alternatives to Novolog.

How to Find Novolog in Stock

If your regular pharmacy doesn't have Novolog, try these strategies:

1. Search on Medfinder: Check real-time pharmacy availability near you.
2. Call independent pharmacies: They often have better access during shortages.
3. Try mail-order pharmacies: Express Scripts, OptumRx, and CVS Caremark may have larger supplies.
4. Contact NovoCare: Call 1-866-310-7549 for help finding stock and accessing savings programs.
5. Ask about pen alternatives: If vials are out of stock, FlexPen or FlexTouch pens may be available.

For a full guide, read How to Find Novolog in Stock Near You.

Final Thoughts

The Novolog supply situation in 2026 is better than it was in 2024, but challenges remain. The discontinuation of unbranded Insulin Aspart, growing demand, and supply chain complexities mean some patients will continue to face stock-outs. Stay proactive — refill early, know your alternatives, and use tools like Medfinder to stay ahead of the shortage.

If you're struggling to find or afford your insulin, you're not alone. Talk to your doctor, explore savings programs, and never skip doses without medical guidance.